Featured Research

from universities, journals, and other organizations

Anti-Diabetic Drug Found To Dramatically Reduce Symptoms Of Bowel Disease That Affects Millions Worldwide

Date:
August 16, 1999
Source:
University Of Pennsylvania Medical Center
Summary:
Researchers at the University of Pennsylvania Medical Center have shown that a class of anti-diabetic agents currently on the market dramatically decreases the symptoms of inflammatory bowel disease in mice. Specifically, they discovered that these drugs inhibit the activation of a master regulator of the inflammatory response called NF-kappa B. Their research suggests that these compounds, called thiazolidinediones (TZDs), may be an effective new therapy for treating inflammatory bowel disease (IBD) in humans, a debilitating disorder that afflicts millions worldwide.

Researchers at the University of Pennsylvania Medical Center have shown that a class of anti-diabetic agents currently on the market dramatically decreases the symptoms of inflammatory bowel disease in mice. Specifically, they discovered that these drugs inhibit the activation of a master regulator of the inflammatory response called NF-kappa B. Their research suggests that these compounds, called thiazolidinediones (TZDs), may be an effective new therapy for treating inflammatory bowel disease (IBD) in humans, a debilitating disorder that afflicts millions worldwide. The investigators present their findings in the August 15 issue of the Journal of Clinical Investigation.

The Penn team found that when they gave TZDs to mice with IBD, it significantly reduced the symptoms of the disease, as measured by a composite index of weight loss, diarrhea, and intestinal bleeding. After about a week of the treatment, there was an 80 percent improvement in the mice receiving TZDs. "We're excited about this because the mouse model in our study has been used for a long time to study treatments for inflammatory bowel disease, and many pharmacologic agents that are effective in humans with IBD are also effective in this animal model," says senior author Gary D. Wu, MD, an assistant professor of medicine.

Inflammatory bowel disease manifests itself in two ways -- one is limited to the colon, which is called ulcerative colitis. The other is Crohn's disease, which can involve the entire gastrointestinal tract. The total number of people in the United States that have either one of those diseases is approximately one million.

The Penn study focused on ulcerative colitis, which affects about 500,000 Americans. "IBD is a chronic disease with waxing and waning activity and is very debilitating in some patients," notes Wu. The symptoms in humans include abdominal pain, diarrhea, intestinal bleeding, nausea, and vomiting.

Many patients fail to respond to currently available therapies. Furthermore, some of the other drugs used to treat moderate to severe IBD, including steroids and other immune modulatory agents, can be toxic to the human system. "Because of this, we've been searching for more effective, safer oral treatments for ulcerative colitis," says Wu.

Using cell cultures, the researchers are also discovering how TZDs work on a molecular basis. By binding to PPAR-gamma, a nuclear hormone receptor, TZDs ultimately inhibit the action of NF-kappa B, a master regulatory molecule in the inflammatory response. PPAR-gamma is localized to the nucleus of cells found in several tissues of the body, including the cells lining the inside of the colon. When an activating molecule, such as a drug like TZD, migrates through the cell membrane and into the nucleus, it binds to PPAR-gamma. This complex, hypothesizes Wu and colleagues, then activates a gene that makes proteins which ultimately inhibit NF-kappa B and the inflammatory response.

Because of what is understood from studies in cell culture and now in animal models about the action of TZDs, the Penn Inflammatory Bowel Disease Center has just started enrolling patients in a clinical trial to see if the drugs will be an effective treatment for ulcerative colitis. They are using a new generation TZD drug called rosiglitazone (Avandia), which was released several weeks ago for the treatment of diabetes.

These studies were funded in part by grants from the National Institutes of Health.


Story Source:

The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pennsylvania Medical Center. "Anti-Diabetic Drug Found To Dramatically Reduce Symptoms Of Bowel Disease That Affects Millions Worldwide." ScienceDaily. ScienceDaily, 16 August 1999. <www.sciencedaily.com/releases/1999/08/990816065944.htm>.
University Of Pennsylvania Medical Center. (1999, August 16). Anti-Diabetic Drug Found To Dramatically Reduce Symptoms Of Bowel Disease That Affects Millions Worldwide. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/1999/08/990816065944.htm
University Of Pennsylvania Medical Center. "Anti-Diabetic Drug Found To Dramatically Reduce Symptoms Of Bowel Disease That Affects Millions Worldwide." ScienceDaily. www.sciencedaily.com/releases/1999/08/990816065944.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Ebola Cases Could Reach 1.4 Million Within 4 Months

Ebola Cases Could Reach 1.4 Million Within 4 Months

Newsy (Sep. 23, 2014) Health officials warn that without further intervention, the number of Ebola cases in Liberia and Sierra Leone could reach 1.4 million by January. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Cases to Triple in Weeks Without Drastic Action

WHO: Ebola Cases to Triple in Weeks Without Drastic Action

AFP (Sep. 23, 2014) The number of Ebola infections will triple to 20,000 by November, soaring by thousands every week if efforts to stop the outbreak are not stepped up radically, the WHO warned in a study on Tuesday. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
5 Ways Men Can Prevent Most Heart Attacks

5 Ways Men Can Prevent Most Heart Attacks

Newsy (Sep. 23, 2014) No surprise here: A recent study says men can reduce their risk of heart attack by maintaining a healthy lifestyle, which includes daily exercise. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins